Drug manufacturers, Pozen Inc. and GlaxoSmithKline Plc on Friday announced the FDA will not approve their newly developed migraine headache drug unless they provide new safety information.
Reuters reports the companies said in a combined release, "The agency has requested additional safety information on Trexima, which may require new studies." The agency admitted the drug was effective, but only issued a conditional approval pending the requested safety information
